Many hospitals have abused the 340B program which was intended to help patients, but healthcare systems saw it as an opportunity to increase their revenue.
I invited Sayeh Nikpay, Ph.D., MPH of Vanderbilt University School of Medicine to explain the origins of 340B, how safety-net clinics, as well as large hospitals, became participants in the program, and the possibility of getting rid of the program altogether.
You want to listen to this one.
Dr Nabhan and the podcast guests have no relevant financial disclosures.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
